Table 5.

Summary of studies on ⁹⁰Y-transarterial radioembolization in liver metastases from various tumor types with more than 10 patients published within the last 5 years

Ref.	Patients (n)	Particle type	Entity	Setting	Design	Response (%)					Median survival (mo)
						CR	PR	SD	AR	PD
Saxena et al[78]	48	Resin	NET	Salvage	Retrospective	15	40	23	78	22	35
Cao et al[79]	58	Resin	NET	Mixed	Retrospective	11.7	27.5	27.5	66.7	33.3	36
Paprottka et al[80]	42	Resin	NET	Mixed	Retrospective	0	22.5	75	97.5	2.5	NA
Memon et al[81]	40	Glass	NET	Mixed	Retrospective	1.2	62.7	32.5	96.4	3.6	34.4
Peker et al[82]	30	Resin	NET	Mixed	Retrospective	3	37	43	83	17	39
Haug et al[83]	58	Resin	Breast	Salvage	Retrospective	0	25	63	88	12	10.8
Cianni et al[84]	52	Resin	Breast	Salvage	Retrospective	0	56	35	91	9	11.5
Saxena et al[85]	40	Resin	Breast	≥ 1.line CTX	Retrospective	5	26	39	70	30	13.6
Gonsalves et al[86]	32	Resin	Uveal Melanoma	Salvage	Retrospective	3	3	56	62	38	10
Michl et al[87]	19	Resin	Pancreas	mixed	Retrospective	0	64.3	0	64.3	45.7	9

CR: Complete response; PR: Partial response; SD: Stable disease; AR: Any response; PD: Progressive disease; NA: Not available; CTX: Chemotherapy; NET: Neuroendocrine tumor.